ECSP034869A - Una composicion para la piel, permeable selectiva inhibidora de ciclooxigenasa-2 - Google Patents

Una composicion para la piel, permeable selectiva inhibidora de ciclooxigenasa-2

Info

Publication number
ECSP034869A
ECSP034869A EC2003004869A ECSP034869A ECSP034869A EC SP034869 A ECSP034869 A EC SP034869A EC 2003004869 A EC2003004869 A EC 2003004869A EC SP034869 A ECSP034869 A EC SP034869A EC SP034869 A ECSP034869 A EC SP034869A
Authority
EC
Ecuador
Prior art keywords
skin
selective inhibitor
ciclooxigenasa
composition
compounds
Prior art date
Application number
EC2003004869A
Other languages
English (en)
Inventor
Rajeev D Gokhale
Guang Wei Lu
Gary D Ewing
Praveen Tyle
Brenda M Stoller
Ashwini Gadre
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ECSP034869A publication Critical patent/ECSP034869A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos farmacéuticos que contienen una droga inhibidora selectiva ciclooxigenasa-2 (COX-2), en particular en aquellos compuestos que son adecuados para la administración en la piel con el fin de procurar un efecto terapéutico local o sistemático. La invención también se refiere a los procesos para la preparación de tales compuestos y a los métodos de tratamiento que comprenden la administración de dichos compuestos en la piel de un individuo que necesite de ellos.
EC2003004869A 2001-05-31 2003-11-28 Una composicion para la piel, permeable selectiva inhibidora de ciclooxigenasa-2 ECSP034869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29483801P 2001-05-31 2001-05-31
US35075601P 2001-11-13 2001-11-13

Publications (1)

Publication Number Publication Date
ECSP034869A true ECSP034869A (es) 2004-07-23

Family

ID=26968778

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004869A ECSP034869A (es) 2001-05-31 2003-11-28 Una composicion para la piel, permeable selectiva inhibidora de ciclooxigenasa-2

Country Status (25)

Country Link
US (1) US20030161867A1 (es)
EP (1) EP1404345A2 (es)
JP (1) JP2004532871A (es)
KR (1) KR20040033286A (es)
CN (1) CN1547474A (es)
AP (1) AP2003002922A0 (es)
BR (1) BR0210104A (es)
CA (1) CA2448627A1 (es)
CO (1) CO5640125A2 (es)
CR (1) CR7173A (es)
CZ (1) CZ20033241A3 (es)
EA (1) EA200301200A1 (es)
EC (1) ECSP034869A (es)
HU (1) HUP0600294A2 (es)
IL (1) IL159100A0 (es)
IS (1) IS7055A (es)
MA (1) MA27030A1 (es)
MX (1) MXPA03010991A (es)
NO (1) NO20035325D0 (es)
OA (1) OA12613A (es)
PL (1) PL367337A1 (es)
SK (1) SK14762003A3 (es)
TN (1) TNSN03127A1 (es)
WO (1) WO2002096435A2 (es)
ZA (1) ZA200309298B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4283507B2 (ja) * 2002-08-02 2009-06-24 久光製薬株式会社 経皮投与用貼付剤
US20040126415A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor
US20040127531A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor
US20050020658A1 (en) * 2002-11-21 2005-01-27 Katsuyuki Inoo Selective cyclooxygenase-2 inhibitor patch
AP2103A (en) * 2003-01-23 2010-02-08 Shire Holdings Ag A skin permeable form of an anagrelide and device therefore
MXPA06003929A (es) * 2003-10-08 2006-07-05 Novartis Ag Composicion farmaceutica que comprende acido 5-metil-2-(2'-cloro-6'-fluoroanilino) -fenilacetico.
WO2005044227A1 (en) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
KR20070097092A (ko) * 2005-01-14 2007-10-02 리포 케미컬즈 인크. 과다색소침착된 피부 치료용 조성물 및 치료방법
US20060251689A1 (en) * 2005-03-30 2006-11-09 Astion Development A/S Treatment or prevention of pruritus
RS50693B (sr) * 2005-06-14 2010-06-30 Uni-Pharma Kleon Tsetis Pharmaceutical Stabilni farmaceutski gel diklofenak natrijuma
US20120040809A1 (en) 2010-08-11 2012-02-16 Formicola Thomas M Stretch-Out Roll Up Bar
US20070243275A1 (en) * 2006-04-13 2007-10-18 Gilbard Jeffrey P Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
FR2905601A1 (fr) * 2006-09-11 2008-03-14 Innoderm Sarl Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
CA2666398C (en) 2006-10-17 2015-08-18 Ed Kisak Diclofenac gel
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
HU227970B1 (en) * 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
DE102007034976A1 (de) 2007-07-26 2009-01-29 Bayer Healthcare Ag Arzneimittel zur transdermalen Anwendung bei Tieren
CA2730787A1 (en) * 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
KR101632091B1 (ko) 2008-10-20 2016-06-20 유니레버 엔.브이. 항미생물 조성물
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
DK2424374T3 (en) 2009-05-01 2018-05-07 Advanced Vision Res Inc Detergent compositions and methods for using the same
WO2011036048A1 (en) 2009-09-24 2011-03-31 Unilever Nv Disinfecting agent comprising eugenol, terpineol and thymol
WO2011041609A2 (en) * 2009-09-30 2011-04-07 Nuvo Research Inc. Topical formulations
WO2011044540A1 (en) 2009-10-09 2011-04-14 Nuvo Research Inc. Topical formulation comprising etoricoxib and a zwitterionic surfactant
WO2011149645A1 (en) * 2010-05-28 2011-12-01 Nuvo Research Inc. Topical etoricoxib formulation
WO2011151171A1 (en) * 2010-05-31 2011-12-08 Unilever Nv Skin treatment composition
JP2012020991A (ja) * 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
BR112013013085B1 (pt) 2010-12-07 2018-02-14 Unilever N.V. Composição de cuidados orais, enxaguante bucal, creme dental, dentífrico, método para desinfetar a cavidade oral e uso de uma composição
JP5683719B2 (ja) 2011-01-04 2015-03-11 イスタ・ファーマシューティカルズ・インコーポレイテッドＩｓｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ベポタスチン組成物
EP2691077B1 (en) * 2011-03-31 2018-05-09 Integumen Ireland Limited Salicylic acid topical formulation
SG11201400977QA (en) * 2011-10-05 2014-04-28 Douglas Pharmaceuticals Ltd Pharmaceutical methods and topical compositions containing acitretin
EA024551B1 (ru) 2011-11-03 2016-09-30 Юнилевер Н.В. Индивидуальная композиция для очищения
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) * 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045965B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CN105073109B (zh) * 2013-03-29 2019-03-22 株式会社AskAt 眼部疾病用治疗剂
EP3086863B2 (en) * 2013-12-24 2023-01-11 The Procter & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
DK3218060T3 (da) * 2014-11-10 2019-12-02 Achelios Therapeutics Inc Spraybare analgetiske sammensætninger
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
CN105663032A (zh) * 2016-02-23 2016-06-15 青岛科技大学 一种维他昔布软膏剂的制备方法
CN106267218A (zh) * 2016-10-18 2017-01-04 华北理工大学 4‑萜品醇脂肪酸酯衍生物及其应用和制备方法
KR102042456B1 (ko) * 2018-03-22 2019-11-08 크리스탈지노믹스(주) 경피흡수제제
WO2019230939A1 (ja) * 2018-05-31 2019-12-05 国立大学法人九州大学 経皮吸収性製剤
RU2685436C1 (ru) * 2018-06-22 2019-04-18 ЗАО "ФармФирма "Сотекс" Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
CA3164165A1 (en) * 2020-01-10 2021-07-15 Robert Bruce Register Topical compositions containing rofecoxib and methods of making and using the same
KR20220001170A (ko) 2020-06-29 2022-01-05 김종림 앙카볼트
KR102619716B1 (ko) * 2020-10-20 2023-12-29 고려대학교 산학협력단 저온에서도 우수한 항균활성을 갖는 항진균용 조성물
US12250946B2 (en) 2020-10-20 2025-03-18 Korea University Research And Business Foundation Antifungal composition having excellent antifungal activity even at low temperature

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3526887B2 (ja) * 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
CA2222138C (en) * 1995-05-25 2008-10-14 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
GEP20032998B (en) * 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
GB2340751B (en) * 1998-08-12 2003-11-05 Edko Trading Representation Pharmaceutical compositions
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
AU3470600A (en) * 1999-01-14 2000-08-01 David Houze Compositions and methods for drug delivery
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2000072883A2 (en) * 1999-06-02 2000-12-07 Aviana Biopharm Pharmaceutical transdermal compositions
IN191512B (es) * 2000-01-21 2003-12-06 Panacea Biotech
CA2415697A1 (en) * 2000-07-13 2002-01-24 James C. Forbes Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
IN191090B (es) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

Also Published As

Publication number Publication date
EP1404345A2 (en) 2004-04-07
WO2002096435A2 (en) 2002-12-05
ZA200309298B (en) 2004-05-12
TNSN03127A1 (fr) 2005-12-23
CN1547474A (zh) 2004-11-17
CZ20033241A3 (cs) 2004-08-18
MXPA03010991A (es) 2004-02-27
IS7055A (is) 2003-11-27
PL367337A1 (pl) 2005-02-21
CA2448627A1 (en) 2002-12-05
HUP0600294A2 (en) 2007-02-28
NO20035325D0 (no) 2003-11-28
AP2003002922A0 (en) 2003-12-31
IL159100A0 (en) 2004-05-12
BR0210104A (pt) 2004-06-08
CR7173A (es) 2004-04-22
JP2004532871A (ja) 2004-10-28
OA12613A (en) 2006-06-09
CO5640125A2 (es) 2006-05-31
EA200301200A1 (ru) 2004-06-24
WO2002096435A3 (en) 2003-05-01
KR20040033286A (ko) 2004-04-21
US20030161867A1 (en) 2003-08-28
MA27030A1 (fr) 2004-12-20
SK14762003A3 (sk) 2004-08-03

Similar Documents

Publication Publication Date Title
AR024384A1 (es) UNA FORMA DE DOSIFICACIoN FARMACÉUTICA DE DISOLUCIoN INSTANTÁNEA Y UN MÉTODO PARA PREPARARLA
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BRPI0415858A (pt) compostos de medicamentos terapêuticos modificados por tocoferol
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
UY26130A1 (es) Compuestos para tratar la obesidad
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
ES2531118T3 (es) Composición farmacéutica que comprende lacosamida y levetiracetamo para uso en el tratamiento de la epilepsia
ES2174073T3 (es) Forma farmaceutica solida para uso oral.
AR109263A2 (es) Composición que comprende moxidectina
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
NO20042805L (no) Nye forbindelser og deres anvendelse innen medisin, fremgangsmate for deres fremstilling og farmaoytiske sammensetninger som inneholder dem
IS7065A (is) Áætlun um lyfjaskammta við meðferð og lyfjasamsetningar til getnaðarvarna í neyð
ECSP034518A (es) Nuevos retinoides para el tratamiento de enfisema
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido
IS6317A (is) Efni og lyf til að koma í veg fyrir endaþarms- og/eða ristilskrabbamein
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
AR043412A1 (es) Formulaciones farmaceuticas que comprenden un agente enmascarante del sabor amargo